Last Price
40.41
Today's Change
+0.99 (2.51%)
Day's Change
39.23 - 40.48
Trading Volume
223,757
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Full Time Employees: 251 251
IPO Date: 2014-11-05 2014-11-05
CIK: 0001582313 0001582313
ISIN: CA98420N1050 CA98420N1050
CUSIP: 98420N105 98420N105
Beta: 1.25 1.25
Last Dividend: 0.00 0.00
Dcf Diff: 37.69 37.69
Dcf: 2.06 2.06
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.